| 27.06 14:42 | dpa-AFX: Ligand Says Its Partner Verona Pharma's Ohtuvayre Approved By FDA For Maintenance Treatment Of COPD |
| 27.06 14:15 | dpa-AFX: *LIGAND PARTNER VERONA PHARMA ANNOUNCES FDA APPROVAL OF OHTUVAYRE FOR MAINTENANCE TREATMENT OF COPD |
| 18.06 14:19 | dpa-AFX: Ligand Says Merck Receives FDA Approval For CAPVAXIVE For Adults |
| 18.06 14:05 | dpa-AFX: *LIGAND SAYS MERCK RECEIVES FDA APPROVAL FOR PNEUMOCOCCAL 21-VALENT CONJUGATE VACCINE FOR ADULTS |
| 30.05 11:56 | dpa-AFX: Biotech Stocks Facing FDA Decision In June 2024 |
| 07.05 22:06 | dpa-AFX: Ligand Pharmaceuticals Inc Q1 Profit Increases, beats estimates |
| 07.05 22:04 | dpa-AFX: *LIGAND PHARMA Q1 REVENUES $30.98 MLN VS. $43.98 MLN LAST YEAR |
| 07.05 22:04 | dpa-AFX: *LIGAND PHARMA Q1 EPS $4.75 VS. $2.33 YEAR AGO |
| 07.05 22:04 | dpa-AFX: *LIGAND PHARMA Q1 NET INCOME $86.14 MLN VS. $41.95 MLN PRIOR YEAR |
| 07.05 21:02 | dpa-AFX: Ligand Pharmaceuticals Q1 24 Earnings Conference Call At 4:30 PM ET |
| 07.05 15:42 | dpa-AFX: Ligand Enters Into $100 Mln Royalty Financing Agreement With Agenus For BOT/BAL Clinical Dvpt. |
| 07.05 13:35 | dpa-AFX: *LIGAND AND AGENUS ENTER $100 MLN ROYALTY FINANCING AGREEMENT |
| 03.04 15:27 | dpa-AFX: Ligand Pharmaceuticals Announces Launch Of Pelthos; Scott Plesha To Assume Leadership Of Pelthos |
| 03.04 15:08 | dpa-AFX: *LIGAND PHARMA ANNOUNCES LAUNCH OF PELTHOS THERAPEUTICS; APPOINTS SCOTT PLESHA AS CEO |
| 27.02 13:15 | dpa-AFX: *LIGAND PHARMA Q4 EPS $1.03 VS LOSS/SHR $1.04 PRIOR YEAR |
| 27.02 13:14 | dpa-AFX: *LIGAND PHARMA Q4 TOTAL REVENUES $28.1 MLN VS $50.38 MLN PRIOR YEAR |
| 27.02 13:14 | dpa-AFX: Ligand Pharmaceuticals Inc Q4 Earnings Summary |
| 27.02 13:04 | dpa-AFX: *LIGAND PHARMA Q4 CORE ADJ. NET INCOME RISES TO $18.6 MLN OR $1.05/SHR FROM $13.0 MLN OR $0.75/SHR LAST YEAR |
| 16.02 14:16 | dpa-AFX: *LIGAND PHARMA APPOINTS RICHARD BAXTER AS SVP OF INVESTMENT OPERATIONS |
| 28.12 08:18 | dpa-AFX: Biotech Stocks Facing FDA Decision In January 2024 |
|
|
